Inflammatory biomarkers, statins, and the risk of stroke: Cracking a clinical conundrum

Circulation

Volumn 105, Issue 22, 2002, Pages 2583-2585

  Ridker, Paul M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cholesterol; Editorials; Inflammation; Statins; Stroke

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; STATINE;

BLOOD PRESSURE MONITORING; CARDIOVASCULAR RISK; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DISEASE MARKER; EDITORIAL; HUMAN; HYPERLIPIDEMIA; INFLAMMATION; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SMOKING HABIT; STROKE; THROMBOEMBOLISM;

ACUTE-PHASE PROTEINS; ANTILIPEMIC AGENTS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CEREBROVASCULAR ACCIDENT; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; INFLAMMATION; MALE; MIDDLE AGED; NUTRITION SURVEYS; PREDICTIVE VALUE OF TESTS; RISK; RISK ASSESSMENT;

EID: 0037024225     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000017822.82512.62     Document Type: Editorial

References (25)

1. Pravastatin therapy and the risk of stroke
2. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S)
3. Reduction of stroke events with pravastatin: The Prospective Pravastatin Pooling (PPP) Project
4. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
5. C-reactive protein and other markers of inflammation in the prediction of cardiovascular events in women
6. C-reactive protein is a strong but nonspecific risk factor of fatal stroke in elderly persons
7. Serum C-reactive protein and self-reported stroke: Findings from the Third National Health and Nutrition Examination Survey
8. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: The Framingham Study
9. Long-term effects of pravastatin on plasma concentration of C-reactive protein
10. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia
11. Effect of statin therapy on C-reactive protein levels: The Pravastatin Inflammation/CRP Evaluation (PRINCE). A randomized trial and cohort study
12. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site
13. Statins as a newly recognized type of immunomodulator
14. Effects of cholesterol and inflammation-sensitive plasma proteins on incidence of myocardial infarction and stroke in men
15. Fibrinogen as a risk factor for stroke and myocardial infarction
16. Prospective study of endogenous tissue plasminogen activator and risk of stroke
17. Plasma concentration of cross-linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men
18. Thrombogenic factors and recurrent coronary events
19. Acute-phase proteins and other systemic responses to inflammation
20. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels
21. C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events
22. Should statin therapy be considered for patients with elevated C-reactive protein? The need for a definitive clinical trial
23. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol: Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group
24. Direct proinflammatory effect of C-reactive protein on human endothelial cells
25. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs